Lilly ’s galcanezumab meets primary endpoint in three Phase III trials for migraine

US-based healthcare firm Eli Lilly and Company has reported positive results from three Phase III EVOLVE-1, EVOLVE-2 and REGAIN clinical trials of galcanezumab to prevent episodic and chronic migraine.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news